30 results about "3-phenylpropanoic acid" patented technology

The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor alpha (PPARalpha), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride).It relates to a substituted phenylpropanoic acid derivatives represented by a general formula (1),their pharmaceutically acceptable salts and their hydrates, and processes for preparing them.

The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA₂, and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].

The present invention relates to a kind of pyrimidine substituted phenylpropionic acid derivative compounds of formula I which includes itsgeometric isomer, enantiomer, diastereoisomer, racemate, and mixture therefore or pharmaceutically acceptable salt thereof. The present invention also relates to the preparation method and use of such compound. Compounds of present invention are useful in the treatment of polycystic kidney disease.

The invention discloses a splitting method for racemic 2-benzene propanoic acid. The splitting method comprises the following steps: using an organic solvent A, an organic solvent B and a phosphate buffer solution containing hydroxypropyl-beta-cyclodextrin to constitute a solvent system according to the volume ratio of 1-8: 2-6: 10, uniformly mixing, and standing for stratification to get an organic phase and a water phase; dissolving racemic 2-benzene propanoic acid with the obtained water phase to prepare a sample; and splitting racemic 2-benzene propanoic acid by adopting high-speed counter-current chromatography, separating a prepeak eluate and a postpeak eluate, and recovering to get levo-2-benzene propanoic acid monomer and dextro-2-benzene propanoic acid monomer. By adopting the method disclosed by the invention to split racemic 2-benzene propanoic acid, the higher separation degree can be achieved; and the method is further suitable for various types of preparation type counter-current chromatographic instruments, and the levo-2-benzene propanoic acid monomer and the dextro-2-benzene propanoic acid monomer can be obtained by separation.

An improved process for preparing 'Nagelienai' features that the p-isopropylbenzoic acid is reduced by the reducer chosen from active Ni and active Pd or Pd-C to become 4-isopropylcyclohexaformic acid, or the mixture of cis-and anti-4-isopropylcyclohexaformic acids are converted to anti-isopropylcyclohexaformic acid under the action of hydroxide of alkali metal, or the anti-4-isopropylcyclohexacyl chloride reacts on D-phenylpropanoic acid in a mixed solvent system, or the Nagelienai from previous step is recrystallized prification in the mixed organic solvent, and the any two, three, or four of above-said steps are combined.

The present invention discloses a method for efficiently synthesizing beta-benzyl butyrolactone having a specific configuration. The method is characterized in that phenylpropionic acid or a derivative thereof is adopted as a starting material, the phenylpropionic acid or the derivative thereof and an oxazolidone chiral prosthetic group are subjected to condensation, a haloacetic acid ester attacks the carbonyl ortho position carbon of the phenylpropionic acid under the effect of a large steric hindrance organic alkali, the prosthetic group is hydrolyzed and recovered after the specific chiral center is successfully constructed, and the corresponding product is subjected to an intramolecular ester exchange reaction to generate the beta-benzyl butyrolactone having the specific configuration. According to the present invention, the prepared beta-benzyl butyrolactone can be used for chemical synthesis of a lot of dibenzyl type lignins having potential medicinal values, and has characteristics of cheap and readily available raw materials, short step, high yield, and high optical purity.

The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like.

A compound represented by the formula (I)

wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.

The invention discloses a preparation method of cigarette precursor-aroma phenylpropionic ester. The preparation method includes steps of dissolving phenylpropionic acid and monohydric alcohol in dried methylene dichloride; stirring for 10-30 minutes, and adding 4-dimethylamino pyridine and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; stirring for 4-12h under room temperature; monitoring reaction by TLC and tracking the reaction end point; adding water in an organic phase and washing; separating liquid, and washing the mixture by saturated sodium chloride solution; separating liquid and drying the organic phase by anhydrous Na2SO4; concentrating and acquiring the crude product; performing column chromatography isolation to obtain the cigarette precursor-aroma phenylpropionic ester. In the invention, phenylpropionic geraniol ester, phenylpropionic-beta-ionol ester can significantly improve the addition in cigarette by comparing with geraniol and beta-ionol matrix; the external aroma variety of the cigarette is not influenced; the cigarette precursor-aroma phenylpropionic ester is applied to cigarette as the cigarette fumette, thus the cigarette thrill and offensive odor can be reduced, and the smoke roundness and comfort can be improved.

The invention relates to a treating agent for removing ethyl alcohol, isopropyl alcohol and octyl alcohol in waste water of an amino resin workshop. The treating agent is formed by compounding 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 1,8-dihydroxy-3-methoxy-6-methylanthraquinone, S(-)-2-amino-6-n-propyl-4,5,6,7-tetrahydrobenzothiazole hydrochloride, 4-octylphenol ethoxylate, 3',4'-dihydroxy-2-(methyl amino)acetophenone hydrochloride, 4-acetoxy-3-methoxy-(2-allyl) benzene, acetic acid-4-methoxy-benzyl ester, 6,6,10-trimethylbicyclo-3,1,1-hep-2-ene, 2-[[1-(3-acethythio-2-methypropionyl)pyrrolidine-2-formyl]amino]-3-phenylpropionic acid and the like. The capacity of the treating agent for complexing with a target substance is high, the complex precipitate forming speed is high, and the removing rate can reach 99.9%.

The invention discloses a series of phenylpropionic acid derivatives, a preparation method thereof, and a use of the derivatives in pharmacy. The derivatives are compounds represented by formula I. Pharmacodynamic experiments show that the compounds of formula I have good agonist activity to GPR120; an in-vivo metabolism research result shows that the compounds of the formula I have good metabolism stability; and unexpectedly, the compounds have substantially higher agonist activity to the GPR120 after a difluoro substitute group is introduced to a phenyl ring at the carboxyl terminal of the compounds of the formula I. The compounds of the formula I can be used for drugs for preventing diabetes, obesity and other metabolic diseases.

The invention relates to a method for producing R-(+)-2-hydroxy-3-phenylpropanoic acid by transforming L-phenylalanine by adopting providencia microbes. The method is simple in process and has important industrial application value.

Disclosed is as represented by Formula I a compound or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof of the present invention can be used as an immunosuppressant. By regulating the transport of leukocytes, and by regulating the cellular transport of lymphocytes, the lymphocytes are gathered in secondary lymphoid tissues, thus improving the integrity of blood vessels to allow for immunosuppression effect, anti-inflammatory activity, and hemostatic effect.

Selective bromination of 2-methyl-2-phenylpropanoic acid in aqueous medium is described to obtain pure 2-(4-bromophenyl)-2-methylpropanoic acid, which is a useful key intermediate in the process of manufacturing pure fexofenadine.

Optical isomers of phenylpropionic acid drugs are a mixture having R-type optical isomer and S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded. A use of the optical isomers includes that the R-type optical isomer is used for manufacturing anti-inflammatory and analgesic drugs and the mixture having the R-type optical isomer and the S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded, is used for manufacturing anti-inflammatory and analgesic drugs. The therapeutic indexes of anti-inflammatory and analgesic drugs of the present optical isomers are all higher than those of the S-type optical isomers and the racemate.